Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatman-Freedman, Aharona, Hershkovitz, Yael, Kaufman, Zalman, Dichtiar, Rita, Keinan-Boker, Lital, Bromberg, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544958/
https://www.ncbi.nlm.nih.gov/pubmed/34570694
http://dx.doi.org/10.3201/eid2711.211886
_version_ 1784589924859641856
author Glatman-Freedman, Aharona
Hershkovitz, Yael
Kaufman, Zalman
Dichtiar, Rita
Keinan-Boker, Lital
Bromberg, Michal
author_facet Glatman-Freedman, Aharona
Hershkovitz, Yael
Kaufman, Zalman
Dichtiar, Rita
Keinan-Boker, Lital
Bromberg, Michal
author_sort Glatman-Freedman, Aharona
collection PubMed
description In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
format Online
Article
Text
id pubmed-8544958
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-85449582021-11-06 Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 Glatman-Freedman, Aharona Hershkovitz, Yael Kaufman, Zalman Dichtiar, Rita Keinan-Boker, Lital Bromberg, Michal Emerg Infect Dis Dispatch In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting. Centers for Disease Control and Prevention 2021-11 /pmc/articles/PMC8544958/ /pubmed/34570694 http://dx.doi.org/10.3201/eid2711.211886 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Glatman-Freedman, Aharona
Hershkovitz, Yael
Kaufman, Zalman
Dichtiar, Rita
Keinan-Boker, Lital
Bromberg, Michal
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title_full Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title_fullStr Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title_full_unstemmed Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title_short Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
title_sort effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544958/
https://www.ncbi.nlm.nih.gov/pubmed/34570694
http://dx.doi.org/10.3201/eid2711.211886
work_keys_str_mv AT glatmanfreedmanaharona effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021
AT hershkovitzyael effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021
AT kaufmanzalman effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021
AT dichtiarrita effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021
AT keinanbokerlital effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021
AT brombergmichal effectivenessofbnt162b2vaccineinadolescentsduringoutbreakofsarscov2deltavariantinfectionisrael2021

Ejemplares similares